Company Overview and News

26
JONE / Jones Energy, Inc. / Jones Jonny - AMENDMENT NO. 1 (Activist Investment)

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
JONE

25
JONE / Jones Energy, Inc. / Jones Jonny - AMENDMENT NO. 1 (Activist Investment)

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
JONE

26
JONE / Jones Energy, Inc. 8-K (Current Report)

2018-05-27 sec.gov
UNITED STATES
JONE

30
JONE / Jones Energy, Inc. 8-K (Current Report)

2018-05-23 sec.gov
UNITED STATES
JONE

26
Jones Energy, Inc. Announces Results of Annual Stockholder Meeting

2018-05-22 globenewswire
AUSTIN, Texas, May 22, 2018 (GLOBE NEWSWIRE) -- Jones Energy, Inc. (NYSE:JONE) (“Jones Energy” or “the Company”) announced today following its annual meeting of stockholders that the nominees for election of Class II Directors, Mike S. McConnell and Hal S. Washburn, have been elected. Secondly, the proposal to amend the Company’s Amended and Restated Certificate of Incorporation permitting the Company to effect a reverse stock split of the Class A common stock and the Class B common stock of not less than 1-for-5 and not more than 1-for-20, at the discretion of the Board of Directors has been approved.
JNEEP JONE

233
U.S. Shale: NAV Analysis Of Anadarko Basin E&Ps

2018-05-10 seekingalpha
These reports value about 50 US shale exploration and production companies (“E&Ps”) based on their net asset values (“NAV”). Each quarter, I expect to publish new reports with updated quarterly information. Also, because I track a substantial amount of information on each company, from time to time I also intend to publish E&P sector wide trends reports.
ARES.PRA QEP PXD CRZO EQT GPOR SNZYP SN XOG PDCE WLL SRCI SM CTLR HKRCP BCEI HK.WS NFX ARES JONE WPX ESTE CLR ECR CPE WPXP GST-A XEC GST-B DVN GST REN PVA PE CXO EPE SCAZP AXAS GST.PRA GST.PRB AREX RSPP JNEEP EGN SWN JAG CDEV MTDR VNOM PVAYQ COG EOG OAS LPI PVAC HK FANG

28
JONE / Jones Energy, Inc. 10-Q (Quarterly Report)

2018-05-04 sec.gov
jone_Current_Folio_10Q Table of Contents
JONE

34
JONE / Jones Energy, Inc. DEF 14A

2018-04-30 sec.gov
jone_Current_Folio_Proxy Table of Contents
JONE

44
JONE / Jones Energy, Inc. PRE 14A

2018-04-20 sec.gov
jone_Current_Folio_Proxy Table of Contents
JONE

26
Jones Energy, Inc. Declares Contingent Convertible Preferred Stock Dividend

2018-04-17 globenewswire
AUSTIN, Texas, April 17, 2018 (GLOBE NEWSWIRE) -- Jones Energy, Inc. (NYSE:JONE) (“Jones Energy” or “the Company”) today announced that its Board of Directors has declared a contingent quarterly dividend per share equal to 8.0% on an annualized basis based on the liquidation preference of $50.00 per share, or $1.00 per share, on the Company’s 8.0% Series A Perpetual Convertible Preferred Stock (the “Preferred Stock”).
JNEEP JONE

33
JONE / Jones Energy, Inc. 8-K (Current Report)

2018-04-17 sec.gov
UNITED STATES
JONE

111
E&P Bottom Of The Barrel Club #18-2: The Market Plays 'Whack-A-Mole'

2018-04-16 seekingalpha
After a 20% run-up in Club stocks in January, prices declined the rest of the quarter by -25%, with the Club finishing with an average return of -9%.
ECR CRC LGCYP LGCYO CRK REN EPE SCAZP BBEP MCEP MCF AREX RXNRP JNEEP XCOO SNZYP BBEPP SN BBPPQ EVEP JONE XCO REXX DNR LGCY WTI BBEPQ PQ

29
JONE / Jones Energy, Inc. 8-K (Current Report)

2018-03-28 sec.gov
UNITED STATES
JONE

26
Jones Energy, Inc. Receives Continued Listing Standard Notice from the NYSE

2018-03-28 globenewswire
AUSTIN, Texas, March 28, 2018 (GLOBE NEWSWIRE) -- Jones Energy, Inc. (NYSE:JONE) (“Jones Energy” or “the Company”) today announced that it received notification on March 23, 2018 from the New York Stock Exchange (“NYSE”) that the Company was noncompliant with certain continued listing standards because the price of the Company’s Class A common stock over a period of 30 consecutive trading days had fallen below $1.
JNEEP DTK JONE

27
Eagle Energy: Q4 2017 Results Reviewed

2018-03-28 seekingalpha
Eagle booked slightly more reserves than in the previous year and, with the sale of Salt Flat, production will fall.
JNEEP HK HKRCP HK.WS GPRK JONE EGRGF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to JONE / Jones Energy, Inc. on message board site Silicon Investor.

Jones Apparel (JNY) Smarty Jones in Preakness
Jones Soda Co. Animator Chuck Jones Dead at 89
The Naked Thread - Big Cajones Not a Myth Bloated Pigs of the Dow Jones Industrial Average
UJSAF: Urban Juice u0026 Soda (Jones Soda) JMED - Jones Pharma (specialty pharmaceutical mfr)
Dow Jones Futures -- A free paper trading service Dow Jones u0026 Co - DJ
CUSIP: 48019R108